Article
Type 2 diabetes risk alleles in peptidyl-glycine alpha-amidating monooxygenase influence GLP-1 levels and response to GLP-1 receptor agonists.
Genome medicine - 29 Mar 2026
Umapathysivam Mahesh M, Araldi Elisa, Hastoy Benoit, Dawed Adem Y, Vatandaslar Hasan, Mayrhofer Johanna E, Lindquist Peter, Silva Pamuditha N, Goga Algera, Trüllinger Geraldine O, Godbersen Svenja, Sengupta Shahana, Kaufmann Adrian, Thomsen Søren Krogsgaard, Hartmann Bolette, Chen Yi-Chun, Jonsson Anna E, Kabakci Hasan, Thaman Swaraj, Grarup Niels, Have Christian T, Pallo Lindsay P, Faerch Kristine, Gjesing Anette P, Nawaz Sameena, Cheeseman Jane, Neville Matthew J, Pedersen Oluf, Walker Mark, Sun Han, Jennison Christopher, Hattersley Andrew T, Rehfeld Jens F, Holman Rury R, Verchere Bruce C, Hansen Torben, Karpe Fredrik, Holst Jens J, Rosenkilde Mette M, Jones Angus G, Ristow Michael, McCarthy Mark I, Pearson Ewan R, Stoffel Markus, Gloyn Anna L
Abstract excerpt
BACKGROUND: Type 2 diabetes (T2D) is a leading cause of morbidity and mortality worldwide. Despite the availability of multiple glucose-lowering agents, only half of individuals with T2D achieve the recommended HbA1c target of < 7.0%. Precision medicine approaches that leverage patient-specific markers offer a promising strategy to improve therapeutic outcomes. The PAM gene encodes the sole enzyme responsible for...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.